STAT | Reporting from the frontiers of health and medicine 中文 关注 STAT+：Life Biosciences 更新其细胞重编程药物青光眼研究进展” Life Biosciences 昨日表示，三名青光眼患者已接受其实验性细胞重编程药物的单次注射，未出现严重不良事件。 STAT+: Life Biosciences share glaucoma study updates for its cellular reprogramming drug statnews.com STAT | Reporting from the frontiers of health and medicine 中文 RSS thenote.app
